BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

394 related articles for article (PubMed ID: 10563540)

  • 1. Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion.
    Dammann HG; Burkhardt F
    Eur J Gastroenterol Hepatol; 1999 Nov; 11(11):1277-82. PubMed ID: 10563540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers.
    Miner PB; Tutuian R; Castell DO; Liu S; Sostek MB
    Clin Ther; 2006 May; 28(5):725-33. PubMed ID: 16861094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of pentagastrin-stimulated gastric acid secretion by pantoprazole and omeprazole in healthy adults.
    Pratha VS; Hogan DL; Lane JR; Williams PJ; Burton MS; Lynn RB; Karlstadt RG
    Dig Dis Sci; 2006 Jan; 51(1):123-31. PubMed ID: 16416224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Replacement of oral proton pump inhibitors with intravenous pantoprazole to effectively control gastric acid hypersecretion in patients with Zollinger-Ellison syndrome.
    Metz DC; Forsmark C; Lew EA; Starr JA; Soffer EF; Bochenek W; Pisegna JR
    Am J Gastroenterol; 2001 Dec; 96(12):3274-80. PubMed ID: 11774936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral and intravenous dosage forms of pantoprazole are equivalent in their ability to suppress gastric acid secretion in patients with gastroesophageal reflux disease.
    Metz DC; Pratha V; Martin P; Paul J; Maton PN; Lew E; Pisegna JR
    Am J Gastroenterol; 2000 Mar; 95(3):626-33. PubMed ID: 10710049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily--a randomized, two-way crossover study.
    Miehlke S; Madisch A; Kirsch C; Lindner F; Kuhlisch E; Laass M; Knoth H; Morgner A; Labenz J
    Aliment Pharmacol Ther; 2005 Apr; 21(8):963-7. PubMed ID: 15813831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: a dose-response study.
    Pisegna JR; Martin P; McKeand W; Ohning G; Walsh JH; Paul J
    Am J Gastroenterol; 1999 Oct; 94(10):2874-80. PubMed ID: 10520836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacodynamic effects of 3-day intravenous treatment with pantoprazole or ranitidine after 10 days of oral ranitidine.
    Ley LM; Becker A; Lühmann R; Sander P; Lücker PW
    Methods Find Exp Clin Pharmacol; 2005; 27(1):25-9. PubMed ID: 15834456
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously.
    Freston J; Chiu YL; Pan WJ; Lukasik N; Täubel J
    Am J Gastroenterol; 2001 Jul; 96(7):2058-65. PubMed ID: 11467632
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of pantoprazole versus other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome.
    Ramdani A; Mignon M; Samoyeau R
    Gastroenterol Clin Biol; 2002 Apr; 26(4):355-9. PubMed ID: 12070410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo.
    Kwon D; Chae JB; Park CW; Kim YS; Lee SM; Kim EJ; Huh IH; Kim DY; Cho KD
    Arzneimittelforschung; 2001; 51(3):204-13. PubMed ID: 11304936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twenty-four-hour intragastric pH profiles and pharmacokinetics following single and repeated oral administration of the proton pump inhibitor pantoprazole in comparison to omeprazole.
    Hartmann M; Theiss U; Huber R; Lühmann R; Bliesath H; Wurst W; Lücker PW
    Aliment Pharmacol Ther; 1996 Jun; 10(3):359-66. PubMed ID: 8791964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lansoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion.
    Dammann HG; Fuchs W; Richter G; Burkhardt F; Wolf N; Walter TA
    Aliment Pharmacol Ther; 1997 Apr; 11(2):359-64. PubMed ID: 9146776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intragastric acid control in non-steroidal anti-inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole.
    Goldstein JL; Miner PB; Schlesinger PK; Liu S; Silberg DG
    Aliment Pharmacol Ther; 2006 Apr; 23(8):1189-96. PubMed ID: 16611280
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of low-dose rabeprazole and omeprazole on gastric acidity: results of a double blind, randomized, placebo-controlled, three-way crossover study in healthy subjects.
    Bruley des Varannes S; Gharib H; Bicheler V; Bost R; Bonaz B; Stanescu L; Delchier JC; Bonnot-Marlier S
    Aliment Pharmacol Ther; 2004 Oct; 20(8):899-907. PubMed ID: 15479362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intragastric pH and serum gastrin during administration of different doses of pantoprazole in healthy subjects.
    Koop H; Kuly S; Flüg M; Eissele R; Mönnikes H; Rose K; Lühmann R; Schneider A; Fischer R; Arnold R
    Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):915-8. PubMed ID: 8889461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pentagastrin-stimulated gastric acid secretion and pharmacokinetics following single and repeated intravenous administration of the gastric H+, K(+)-ATPase-inhibitor pantoprazole (BY1023/SK&F96022) in healthy volunteers.
    Simon B; Müller P; Hartmann M; Bliesath H; Lühmann R; Huber R; Bohnenkamp W; Wurst W
    Z Gastroenterol; 1990 Sep; 28(9):443-7. PubMed ID: 2177296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rabeprazole is superior to omeprazole for the inhibition of peptone meal-stimulated gastric acid secretion in Helicobacter pylori-negative subjects.
    Ohning GV; Walsh JH; Pisegna JR; Murthy A; Barth J; Kovacs TO
    Aliment Pharmacol Ther; 2003 May; 17(9):1109-14. PubMed ID: 12752347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Acid-supressing capacity of omeprazole 20 mg tablets vs pantoprazole 20 and 40 mg tablets. A pilot study in volunteers].
    Corti R; Améndola R; Menéndez G; Diwecj J; Schenone L; Soutric J; Caruso N
    Acta Gastroenterol Latinoam; 2003; 33(4):199-203. PubMed ID: 14708472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24-h intragastric acidity and plasma gastrin concentrations in young healthy male subjects.
    Williams MP; Sercombe J; Hamilton MI; Pounder RE
    Aliment Pharmacol Ther; 1998 Nov; 12(11):1079-89. PubMed ID: 9845397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.